Open AccessApremilast for oral ulcers associated with active Behçet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial
Author(s) -
Gülen Hatemi,
Alfred Mahr,
Mitsuhiro Takeno,
Do Young Kim,
David Saadoun,
Haner Di̇reskeneli̇,
Melike Melikoğlu,
Sue Cheng,
Shan McCue,
Maria Paris,
Mindy Chen,
Yusuf Yazıcı
Publication year - 2021
Publication title -
clinical and experimental rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.184
H-Index - 95
eISSN - 1593-098X
pISSN - 0392-856X
DOI - 10.55563/clinexprheumatol/ra8ize
Subject(s) - apremilast , medicine , placebo , adverse effect , discontinuation , nausea , clinical endpoint , randomized controlled trial , disease , psoriatic arthritis , alternative medicine , pathology
This study assessed the efficacy and safety of apremilast for the oral ulcers associated with Behçet's syndrome (BS) up to 64 weeks.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom